Osteogenesis Imperfecta – Pipeline Review, H2 2018

Global Markets Direct’s, ‘Osteogenesis Imperfecta – Pipeline Review, H2 2018’, provides an overview of the Osteogenesis Imperfecta pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Osteogenesis Imperfecta, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteogenesis Imperfecta and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Osteogenesis Imperfecta

– The report reviews pipeline therapeutics for Osteogenesis Imperfecta by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Osteogenesis Imperfecta therapeutics and enlists all their major and minor projects

– The report assesses Osteogenesis Imperfecta therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Osteogenesis Imperfecta

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Osteogenesis Imperfecta

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Osteogenesis Imperfecta pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Amgen Inc

Bone Therapeutics SA

Genzyme Corp

Mereo Biopharma Group Plc

Mesentech Inc

SOM Biotech SL

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Osteogenesis Imperfecta Overview

Osteogenesis Imperfecta Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Osteogenesis Imperfecta Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Osteogenesis Imperfecta Companies Involved in Therapeutics Development

Amgen Inc

Bone Therapeutics SA

Genzyme Corp

Mereo Biopharma Group Plc

Mesentech Inc

SOM Biotech SL

Osteogenesis Imperfecta Drug Profiles

ALLOB Drug Profile

Product Description

Mechanism Of Action

R&D Progress

denosumab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug for Osteogenesis Imperfecta Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fresolimumab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

setrusumab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize EP4 Receptor for Osteoporosis and Osteogenesis Imperfecta Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Osteogenesis Imperfecta Dormant Projects

Osteogenesis Imperfecta Discontinued Products

Osteogenesis Imperfecta Product Development Milestones

Featured News & Press Releases

Nov 13, 2017: Mereo Receives EMA PRIME Designation for BPS-804 to Treat Osteogenesis Imperfecta

May 04, 2017: Initiation of BPS-804 potentially pivotal Phase 2b study in patients with osteogenesis imperfecta, an orphan disease

Feb 20, 2017: Mereo BioPharma: BPS-804 accepted for EMA Adaptive Pathways programme

Jun 30, 2016: Mereo’s BPS-804 granted EU Orphan Drug status for Osteogenesis Imperfecta

Mar 02, 2016: Mereo BPS-804 granted U.S. orphan drug status for osteogenesis imperfecta

Oct 01, 2013: Bone Therapeutics receives clearance for ALLOB phase I/IIa trial

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Osteogenesis Imperfecta, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Osteogenesis Imperfecta Pipeline by Amgen Inc, H2 2018

Osteogenesis Imperfecta Pipeline by Bone Therapeutics SA, H2 2018

Osteogenesis Imperfecta Pipeline by Genzyme Corp, H2 2018

Osteogenesis Imperfecta Pipeline by Mereo Biopharma Group Plc, H2 2018

Osteogenesis Imperfecta Pipeline by Mesentech Inc, H2 2018

Osteogenesis Imperfecta Pipeline by SOM Biotech SL, H2 2018

Osteogenesis Imperfecta Dormant Projects, H2 2018

Osteogenesis Imperfecta Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Osteogenesis Imperfecta, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports